This site is intended for health professionals only

Published on 25 September 2007

Share this story:
Twitter
LinkedIn

mCRC drug Vectibix receives EU recommendation

teaser

A drug which helps treat patients suffering from refractory metastatic colorectal cancer with nonmutated (wild-type) KRAS genes is being recommended for use in the EU.

The EMEA’s Committee for Medicinal Products for Human Use (CHMP) has said conditional marketing authorisation should be granted for Vectibix® (panitumumab), which is manufactured by Amgen.

Vectibix is the first fully human IgG2 monoclonal antibody (MAb) which targets the epidermal growth factor receptor (EGFr), a protein that plays an important role in cancer cell signalling.

Phase III trials are now exploring the potential of administering Vectibix in combination with chemotherapy for first- and second-line metastatic colorectal cancer.

Dr Willard Dere, senior vice-president and international chief medical officer at Amgen, commented: “We are pleased that Vectibix has received a positive opinion for conditional approval so patients in the EU have further treatment options for metastatic colorectal cancer. This is an important step forward in personalised cancer care.”

Copyright © PA Business 2007

Amgen



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn